These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 11558453)

  • 21. [Modern fluoroquinolones (ciprofoxacin, levofloxacin) and the treatment of skin and soft tissue infections].
    Iakovlev VP; Svetukhin AM; Blatun LA; Ukhin SA
    Antibiot Khimioter; 2004; 49(8-9):57-65. PubMed ID: 15727148
    [No Abstract]   [Full Text] [Related]  

  • 22. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
    Scoper SV
    Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical effects and bronchoalveolar transfer of levofloxacin in patients with community-acquired pneumonia.
    Lin Y; Su W; Xu Z; Bai Y
    Chin Med J (Engl); 2001 Feb; 114(2):212-3. PubMed ID: 11780213
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical application of levofloxacin for severe infections.
    Tumminello B; Karaniewsky R; Gutierrez-Solana M
    Chemotherapy; 2006; 52(6):321. PubMed ID: 17047427
    [No Abstract]   [Full Text] [Related]  

  • 25. New generations of quinolones: with particular attention to levofloxacin.
    Ambrose PG; Owens RC; Quintiliani R; Nightingale CH
    Conn Med; 1997 May; 61(5):269-72. PubMed ID: 9197076
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of ciprofloxacin and ofloxacin using human corneal susceptibility levels.
    Kowalski RP; Karenchak LM; Gordon YJ
    Cornea; 1998 May; 17(3):282-7. PubMed ID: 9603384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial susceptibility testing of newer quinolones against gram positive and gram negative clinical isolates.
    Iffat W; Shoaib MH; Muhammad IN; Rehana ; Tasleem S; Gauhar S
    Pak J Pharm Sci; 2010 Jul; 23(3):245-9. PubMed ID: 20566434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Levofloxacin. expediency of high-dose regimens in therapy of lower respiratory tract infections].
    Guchev IA; Melekhina EV; Iudenich OV
    Antibiot Khimioter; 2011; 56(3-4):17-31. PubMed ID: 21913405
    [No Abstract]   [Full Text] [Related]  

  • 30. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
    Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levofloxacin in the treatment of ventilator-associated pneumonia.
    Alvarez-Lerma F; Grau S; Alvarez-Beltrán M
    Clin Microbiol Infect; 2006 May; 12 Suppl 3():81-92. PubMed ID: 16669931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [[New antimicrobial agent series XLVII]: levofloxacin].
    Saito A
    Jpn J Antibiot; 1994 Apr; 47(4):309-32. PubMed ID: 8201762
    [No Abstract]   [Full Text] [Related]  

  • 33. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
    Wise R; Andrews JM
    J Chemother; 1998 Aug; 10(4):276-9. PubMed ID: 9720464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity and durability of a combination of an antibiofilm and an antibiotic against vascular catheter colonization.
    Mansouri MD; Hull RA; Stager CE; Cadle RM; Darouiche RO
    Antimicrob Agents Chemother; 2013 Jan; 57(1):621-5. PubMed ID: 23114776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sparfloxacin and levofloxacin.
    Med Lett Drugs Ther; 1997 Apr; 39(999):41-3. PubMed ID: 9137295
    [No Abstract]   [Full Text] [Related]  

  • 36. Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial.
    Chen Y; Yang H; Lu G; Wu X; Huang W; Wu Y; Lv X; Wu G; Zhang G; Li Q; Sun Y
    Chemotherapy; 2012; 58(3):249-56. PubMed ID: 22890091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levofloxacin-resistant pneumococcus.
    Klugman KP
    Clin Infect Dis; 2000 Aug; 31(2):626-7. PubMed ID: 10987743
    [No Abstract]   [Full Text] [Related]  

  • 38. New quinolones, ofloxacin and levofloxacin, inhibit telomerase activity in transitional cell carcinoma cell lines.
    Yamakuchi M; Nakata M; Kawahara K; Kitajima I; Maruyama I
    Cancer Lett; 1997 Nov; 119(2):213-9. PubMed ID: 9570374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of a new quinolone, levofloxacin in patients with surgical infections.
    Morimoto K; Kinoshita H; Nakatani S; Sakai K; Fujimoto M; Ohno K; Ueda T; Ohmori K; Yamazaki O; Doi S
    Jpn J Antibiot; 1992 Mar; 45(3):258-64. PubMed ID: 1512922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of ofloxacin--measurement of drug concentration in saliva of patients with impaired renal function.
    Fujita K; Matsuoka N; Takenaka I; Hiraishi K; Yokota T; Asahi T; Tatara K; Yuasa M; Kaifu Y; Kawano A
    Drugs; 1995; 49 Suppl 2():312-3. PubMed ID: 8549345
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.